S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
Log in

NASDAQ:PHIOPhio Pharmaceuticals Stock Price, Forecast & News

$1.69
0.00 (0.00 %)
(As of 04/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.63
Now: $1.69
$1.75
50-Day Range
$1.68
MA: $2.63
$3.33
52-Week Range
$1.60
Now: $1.69
$28.05
Volume128,696 shs
Average Volume273,705 shs
Market Capitalization$1.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. The company has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHIO
CUSIPN/A
CIKN/A
Phone508-767-3861

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Book Value$8.59 per share

Profitability

Net Income$-8,910,000.00

Miscellaneous

Employees9
Market Cap$1.10 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive PHIO News and Ratings via Email

Sign-up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.


Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions

How has Phio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHIO stock has decreased by 39.0% and is now trading at $1.69. View which stocks have been mosted impacted by Coronavirus.

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Phio Pharmaceuticals.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp (NASDAQ:PHIO) issued its quarterly earnings data on Thursday, March, 26th. The company reported ($4.69) EPS for the quarter, missing analysts' consensus estimates of ($4.40) by $0.29. View Phio Pharmaceuticals' earnings history.

Has Phio Pharmaceuticals been receiving favorable news coverage?

News articles about PHIO stock have been trending very negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Phio Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutPhio Pharmaceuticals.

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 42,800 shares, an increase of 664.3% from the February 27th total of 5,600 shares. Based on an average trading volume of 603,500 shares, the short-interest ratio is presently 0.1 days. Currently, 6.5% of the shares of the stock are short sold. View Phio Pharmaceuticals' Current Options Chain.

Who are some of Phio Pharmaceuticals' key competitors?

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include Gilead Sciences (GILD), General Motors (GM), Target (TGT), Baidu (BIDU), Celsion (CLSN), DelMar Pharmaceuticals (DMPI), LYFT (LYFT), Ocugen (OCGN), People's United Financial (PBCT) and Tilray (TLRY).

Who are Phio Pharmaceuticals' key executives?

Phio Pharmaceuticals' management team includes the following people:
  • Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc, Pres & CEO (Age 44)
  • Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 33)

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $1.69.

How big of a company is Phio Pharmaceuticals?

Phio Pharmaceuticals has a market capitalization of $1.10 million and generates $20,000.00 in revenue each year. The company earns $-8,910,000.00 in net income (profit) each year or ($19.33) on an earnings per share basis. Phio Pharmaceuticals employs 9 workers across the globe. View additional information about Phio Pharmaceuticals.

What is Phio Pharmaceuticals' official website?

The official website for Phio Pharmaceuticals is http://phiopharma.com/.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at 508-767-3861 or via email at http://investors.phiopharma.com.

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel